Abstract: For a long-term efficient drug-eluting stent for vascular applications, the development of drug-loaded coating, combining the effective inhibition of smooth muscle cell proliferation while promoting the re-endothelialization, is a promising concept. However the mostly required simultaneous incorporation of drugs can influence decisively the stability, efficacy and release of the respective drug. Therefore, the mutual influence of a dual local drug delivery coatings based on poly(L-lactide-co-ε-caprolactone) (PLLAco-CL) containing vascular endothelial growth factor (VEGF 165 ) coupled to the surface and an embedded drug, such as fluorescein diacetate (FDAc) instead of Paclitaxel (PTX) on the in vitro drug release was investigated. Surprisingly, for the investigated coating the immobilized VEGF loading was enhanced and the release profile was accelerated by FDAc incorporation. Even a manifold increase for the in vitro released amounts of VEGF was detected. In contrast, the immobilization of VEGF seems to have a negligible influence on the in vitro FDAc release profiles.
Introduction
Drug-eluting stents (DES) were a breakthrough in atherosclerotic vascular disease treatment [1] . DES with Paclitaxel (PTX) as cytostatic drug reduce neointimal hyperplasia by inhibition of smooth muscle cell proliferation [2, 3] . A side action is the arresting of the endothelial cell proliferation and growth resulting in increased risk of late instent thrombosis [4, 5] .
Promising approaches to improve the long-term efficacy of DES by minimizing neointimal hyperplasia and promoting the re-endothelialization are the use of biodegradable polyesters and surface modifications [6] [7] [8] [9] . Our studies focus on the development of a dual local drug delivery coating for DES combining the effective inhibition of smooth muscle cell proliferation while promoting the re-endothelialization. To avoid stability, efficacy and release issues of combined incorporated drugs we used bulk drug incorporation with surface immobilization.
Therefore, we developed a dual local drug delivery coating based on poly(L-lactide-co-ε-caprolactone) (PLLAco-CL) with vascular endothelial growth factor (VEGF 165 ), a potent mitogen for endothelial cells [10] , for surface immobilization. As model drug for bulk incorporation we used fluorescein diacetate (FDAc) with diffusion and distribution coefficients similar to paclitaxel [11] . To immobilize VEGF we generated functional groups on the polymer surface via an established oxygen plasma procedure which also improves hemocompatibility of PLLA-co-CL [12] . The immobilization of VEGF occurs by the formation of ester bonds and the release of VEGF by their hydrolysis [13] .
Material and methods
The polymer poly(L-lactide-co-ε-caprolactone (P(LLA-co-CL), Purasorb PLC 7015) was acquired from Corbion (Amsterdam, The Netherlands). Fisher Scientific GmbH (Schwerte, Germany) was supplier for the crosslinker bis(sulfosuccinimidyl) suberate (BS 3 ) and tebu-bio GmbH (Offenbach, Germany) for human vascular endothelial growth factor (VEGF). Fluorescein diacetate (FDAc) and Paclitaxel (PTX) were bought from Fisher Scientific GmbH (Schwerte, Germany) and Cfm Oskar Tropitzsch GmbH (Marktredwitz, Germany).
Coating preparation
Coatings were prepared via an established and characterized spray coating process. Clean glass slides (Ø = 6 mm) were coated with 250 µg pure polymer or polymer/drug mixture. Polymer drug ratio was always 82.5 to 17.5%. We used a chloroform P(LLA-co-CL) (0.13% w) spray solution.
Immobilization of human VEGF165 on P(LLA-co-CL) coatings was carried out via covalently coupling. At first the polymer was activated via oxygen (O 2 )-plasma according to Rudolph et al. [12] followed by an incubation in a BS 3 phosphate buffered saline solution (PBS, pH 7.6) for 30 min at room temperature. After rinsing with PBS and water samples were immersed in PBS with VEGF (1 µg/mL) for 1 h at room temperature. After a repeated rinsing step samples were dried under vacuum overnight.
Surface characterisation
A Contact Angle System (OCA 20, Dataphysics Instruments GmbH, Filderstadt, Germany) was used for analysing surface modifications by contact angle measurements of ultra-pure water sessile drops. Presented mean values and standard deviations were calculated from n = 5 samples.
An avidin-biotin-complex enzyme-linked immunosorbent assay (ABC-ELISA) was used for VEGF loading determination according to [13] . Horseradish peroxidase catalysed transformation of 3,3´,5,5´-tetramethylbenzidine was measured by using a plate reader (FLUOstar Optima, BMG LABTECH, Ortenberg, Germany). Mean values and standard deviations were calculated from five individual specimens.
Release studies
The FDAc in vitro release studies were adapted according to Mogal et al. [14] . Each sample (Ø = 6 mm) was immersed in 300 µL cell culture medium MCDB131 (PAN Biotech, Aidenbach, Germany). Release occurs under dark and shaken conditions at 37 °C. At defined time points release media were completely removed for analyses and replaced by fresh culture media. Fluorescence (excitation/emission 490/520) was determined via plate reader (FLUOstar Optima, BMG LABTECH, Ortenberg, Germany). Total released FDAc at several time points in comparison to the immobilized amount of FDAc are presented.
The VEGF in vitro release studies were carried out according to Teske et al. [13] in 0.35 mL cell culture medium MCDB131 for each samples (Ø = 6 mm). The release of VEGF after covalent coupling occurs by hydrolysis of formed ester bonds during coupling. VEGF amount in media was determined by a Sandwich ELISA (Human VEGF ELISA Kit RayBio®, Hölzel Diagnostika, Köln, Germany) according to manufacturer's instructions.
Results

Immobilization and in vitro release of FDAc and VEGF
In this investigation FDAc was used instead of Paclitaxel (PTX) due to the described similar release behavior [11] . P(LLA-co-CL) samples with FDAc incorporated were produced via a spray coating process and the surfaces for the additional biofunctionalization with VEGF were characterized via contact angle measurements. The contact angle of the surfaces of P(LLA-co-CL) and P(LLA-co-CL)_FDAc is rather similar. Only after O 2 -plasma activation the angle is decreased ( Table 1) . For P(LLA-co-CL) the contact angle is decreased of about 10 ° for P(LLA-co-CL)_FDAc 18 °.
VEGF was immobilized on the polymer surfaces via hydrolytic cleavable ester bonds with BS 3 as crosslinking agent.
The absolute VEGF loading was analyzed via the ELISA technique. The highest quantity of immobilized VEGF was detected for the O 2 -plasma activated FDAc containing system with 4 ng per sample. For the O 2 plasma activated pure P(LLAco-CL) 2 ng per sample were observed.
The in vitro release studies of FDAc and VEGF from the examined P(LLA-co-CL) samples are shown in Figure 1 . The VEGF coupling on P(LLA-co-CL) seems to influence the in vitro release of FDAc negligible (Figure 1 A) . Within 192 h the release profile and the released amount are similar with or without VEGF surface immobilization. In contrast, the P(LLA-co-CL)_FDAc system crucially influences the loading as well as the release profile of VEGF. The amount of released VEGF is higher for P(LLA-co-CL)_FDAc_VEGF compared to the FDAc free polymer systems.
Discussion
After promising studies with P(LLA-co-CL) [10] and an established spray coating process (data not shown) we further evaluate a dual drug delivery system for DES to improve reendothelialization. As model drug for PTX we used FDAc due to the similar diffusion and distribution coefficients [11] . During our screenings the highest VEGF loading was detected for BS 3 as crosslinker. Furthermore the immobilization is realized by hydrolytic cleavable ester bonds as it is known that surface immobilized VEGF enhance reendothelialization [10, 15] . Furthermore, our systems revealed rather similar FDAc release profiles only slightly influenced by the VEGF surface immobilization. In contrast FDAc incorporation doubled the VEGF loading capacity per sample and also the released amount of VEGF. Presumably, FDAc provided additional functional groups and therefore acts like an anchor for reactions with the Crosslinker molecules. In summary, our studies suggest that the drug delivery system P(LLA-co-CL)_FDAc_VEGF may be a promising dual drug delivery system. Ongoing investigations are focused on the use of the established PTX instead of FDAc as incorporated drug. Preliminary analysis revealed the compensation of the endothelial cell inhibitory effect of PTX by surface immobilized VEGF.
